Geron Co. (NASDAQ:GERN) EVP Melissa Kelly Behrs sold 120,635 shares of the firm’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $2.00, for a total value of $241,270.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Geron stock opened at $2.00 on Thursday. The company has a market cap of $339.26 million, a P/E ratio of -12.50 and a beta of 2.95. Geron Co. has a one year low of $0.95 and a one year high of $6.99.

Geron (NASDAQ:GERN) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). Geron had a negative return on equity of 17.61% and a negative net margin of 2,534.43%. The business had revenue of $0.38 million during the quarter, compared to the consensus estimate of $0.22 million. On average, analysts forecast that Geron Co. will post -0.34 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in GERN. FMR LLC increased its holdings in Geron by 158.4% during the 4th quarter. FMR LLC now owns 15,536,850 shares of the biopharmaceutical company’s stock valued at $15,537,000 after purchasing an additional 9,523,953 shares in the last quarter. Millennium Management LLC increased its holdings in Geron by 242.5% during the 4th quarter. Millennium Management LLC now owns 736,307 shares of the biopharmaceutical company’s stock valued at $736,000 after purchasing an additional 1,253,007 shares in the last quarter. BlackRock Inc. increased its holdings in Geron by 7.9% during the 4th quarter. BlackRock Inc. now owns 15,038,176 shares of the biopharmaceutical company’s stock valued at $15,037,000 after purchasing an additional 1,102,419 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Geron during the 4th quarter valued at $985,000. Finally, Vanguard Group Inc increased its holdings in Geron by 8.2% during the 3rd quarter. Vanguard Group Inc now owns 8,751,607 shares of the biopharmaceutical company’s stock valued at $15,403,000 after purchasing an additional 661,446 shares in the last quarter. 33.54% of the stock is owned by hedge funds and other institutional investors.

GERN has been the subject of several analyst reports. ValuEngine downgraded Geron from a “hold” rating to a “sell” rating in a research report on Monday, December 17th. B. Riley upgraded Geron from a “neutral” rating to a “buy” rating and raised their target price for the stock from $1.50 to $3.25 in a research report on Thursday, January 31st. BTIG Research initiated coverage on Geron in a research report on Tuesday, February 12th. They set a “buy” rating and a $4.00 target price for the company. BidaskClub upgraded Geron from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. Finally, Needham & Company LLC upgraded Geron from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Tuesday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $3.31.

TRADEMARK VIOLATION NOTICE: “Geron Co. (GERN) EVP Melissa Kelly Behrs Sells 120,635 Shares” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/geron-co-gern-evp-melissa-kelly-behrs-sells-120635-shares/2954660.html.

About Geron

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Recommended Story: How do taxes affect a CDs total return?

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.